Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model

FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease

(2013) Alba Di Pardo et al.   HUMAN MOLECULAR GENETICS

Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline

(2013) Ralf Reilmann   MOVEMENT DISORDERS

A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease

(2013)   MOVEMENT DISORDERS

One-year safety and tolerability profile of pridopidine in patients with Huntington disease

(2013) F. Squitieri et al.   NEUROLOGY

Changes in brainstem serotonergic and dopaminergic cell populations in experimental and clinical Huntington’s disease

(2013) A. Jahanshahi et al.   NEUROSCIENCE

Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-κB pathway

(2013) A Hyrskyluoto et al.   Cell Death & Disease

The dopaminergic stabilizer, (−)-OSU6162, rescues striatal neurons with normal and expanded polyglutamine chains in huntingtin protein from exposure to free radicals and mitochondrial toxins

(2012) C. Ruiz et al.   BRAIN RESEARCH

The dopamine stabilizers ACR16 and (−)-OSU6162 display nanomolar affinities at the σ-1 receptor

(2012) K Sahlholm et al.   MOLECULAR PSYCHIATRY

Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology

(2012) M. J. Armstrong et al.   NEUROLOGY

Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice

(2012) Z. R. Crook et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice

(2012) A. Di Pardo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders

(2011) Teruo Hayashi et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

(2011) Justo Garcia de Yebenes et al.   LANCET NEUROLOGY

The Physiology, Signaling, and Pharmacology of Dopamine Receptors

(2011) J.-M. Beaulieu et al.   PHARMACOLOGICAL REVIEWS

Altered Dopamine and Serotonin Metabolism in Motorically Asymptomatic R6/2 Mice

(2011) Fanny Mochel et al.   PLoS One

Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease

(2010) Anders Lundin et al.   CLINICAL NEUROPHARMACOLOGY

Dopamine and Glutamate in Huntington's Disease: A Balancing Act

(2010) Véronique M. André et al.   CNS Neuroscience & Therapeutics

In vivo pharmacology of the dopaminergic stabilizer pridopidine

(2010) Henrik Ponten et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Impaired Ganglioside Metabolism in Huntington's Disease and Neuroprotective Role of GM1

(2010) V. Maglione et al.   JOURNAL OF NEUROSCIENCE

Poster 19: Validation of the Modified Motor Score (mMS): A Subscale of the Unified Huntington's Disease Rating Scale (UHDRS) Motor Score

(2010) S. Waters et al.   Neurotherapeutics